Lumiliximab, also known as ST-152, represents a promising antibody targeting the soluble receptor for IL-13. This specific agent demonstrates impressive potential in addressing fibrotic diseases , https://andrewtlye249336.activoblog.com/51399473/lumiliximab-a-thorough-dive-into-the-st-152-monoclonal